Compare T-Mobile Us Inc (TMUS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Mobile Us Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? T-Mobile Us Inc trades at $158.44 (market cap $164.91B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: T-Mobile Us Inc is far larger — about 33.8× Travere Therapeutics Inc. Common Stock's market cap, and T-Mobile Us Inc pays a 3.04% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold T-Mobile Us Inc for 84 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TMUS | TVTX | |
|---|---|---|
Market Cap | $164.91B | $4.88B |
Volume | 5,684,850 | 1,668,577 |
Sector | Media | Health |
52-Week High | $230.06 | $67.52 |
52-Week Low | $148.58 | $26.79 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $281.53B | $5.01B |
Dividend Yield | 3.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T-Mobile US (TMUS) trades at $157.79, up 3.9% with strong recent earnings beats but faces technical bearish signals. The company maintains robust fundamentals with $88.31B revenue (2025), 11.45% net margin, and attractive valuation ratios (P/E 16.08, EV/EBITDA 8.73). Recent developments include a 15% dividend hike and AI-powered 5G network enhancements, though debt levels remain elevated at $84.6B.
TMUS presents a compelling growth story with solid profitability and analyst support (81% buy rating, $221.75 target), but investors must weigh technical weakness against fundamental strength. Key risks include competitive pressures, macroeconomic uncertainty, and the company's substantial debt load in a rising rate environment.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
